Abstract
BackgroundOlfactory neuroblastoma (ONB) is a rare tumor originating from olfactory epithelium. Here we retrospectively analyzed the long-term treatment outcomes and toxicity of radiotherapy for ONB patients for whom computed tomography (CT) and three-dimensional treatment planning was conducted to reappraise the role of radiotherapy in the light of recent advanced technology and chemotherapy.MethodsSeventeen patients with ONB treated between July 1992 and June 2013 were included. Three patients were Kadish stage B and 14 were stage C. All patients were treated with radiotherapy with or without surgery or chemotherapy. The radiation dose was distributed from 50 Gy to 66 Gy except for one patient who received 40 Gy preoperatively.ResultsThe median follow-up time was 95 months (range 8–173 months). The 5-year overall survival (OS) and relapse-free survival (RFS) rates were estimated at 88% and 74%, respectively. Five patients with stage C disease had recurrence with the median time to recurrence of 59 months (range 7–115 months). Late adverse events equal to or above Grade 2 in CTCAE v4.03 were observed in three patients.ConclusionMultimodal therapy including radiotherapy with precise treatment planning based on CT simulation achieved an excellent local control rate with acceptable toxicity and reasonable overall survival for patients with ONB.
Highlights
Olfactory neuroblastoma (ONB), or esthesioneuroblastoma, is a rare tumor originating from olfactory epithelium
We retrospectively investigated the patients with ONB who were treated with the computed tomography (CT) simulation
The purpose of this study was to analyze the relationship between treatment modalities, survival, tumor control, and the acute and late toxicity of patients treated for ONB with radiotherapy with or without surgery or chemotherapy
Summary
Olfactory neuroblastoma (ONB), or esthesioneuroblastoma, is a rare tumor originating from olfactory epithelium. In a meta-analysis of studies published from 1990 through 2000, the cases of 390 patients were reported in 26 studies, and the averaged overall and disease-free survival rates at 5 years were 45% and 41%, respectively [1]. 26% of the United States population [2] Those authors showed that the 5-year overall survival stratified by treatment modality was 73% for surgery with radiotherapy, 68% for surgery only, 35% for radiotherapy only, Mori et al Radiation Oncology (2015) 10:88 and 26% for neither surgery nor radiotherapy, suggesting that surgery with radiotherapy is the optimal strategy. We retrospectively analyzed the long-term treatment outcomes and toxicity of radiotherapy for ONB patients for whom computed tomography (CT) and three-dimensional treatment planning was conducted to reappraise the role of radiotherapy in the light of recent advanced technology and chemotherapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
